Show simple item record

dc.contributor.authorElliott, Tom
dc.contributor.authorWhiteman, David C.
dc.contributor.authorOlsen, Catherine M.
dc.contributor.authorGordon, Louisa G.
dc.date.accessioned2018-06-25T12:30:43Z
dc.date.available2018-06-25T12:30:43Z
dc.date.issued2017
dc.identifier.issn1175-5652
dc.identifier.doi10.1007/s40258-017-0341-y
dc.identifier.urihttp://hdl.handle.net/10072/349530
dc.description.abstractBackground: Skin cancer exerts a large and growing burden on health systems. With new pharmacotherapies for metastatic melanoma now available, a contemporary understanding of the cost burden of melanoma control is warranted. Objective: To comprehensively assess the healthcare costs of malignant melanoma diagnosis and treatment in Australia, over 3 years after diagnosis. Methods: We developed a decision-analytic model and micro-costing method to estimate the mean cost per patient for melanoma, incorporating all diagnostic and treatment modalities used in Australia (2017 AU$). By using the de-identified 10% sample of Medicare Benefits Scheme, we analysed health service use and supplemented our analyses with published estimates. We took a health system cost perspective, and addressed input uncertainty with sensitivity analyses. Results: The mean annual cost per patient for melanoma stage 0/I/II was AU$1681 (US$1175) rising to AU$37,729 (US$26,365) for stage III resectable, and AU$115,109 (US$80,440) for stage III unresectable/IV. Three-year costs for stage III unresectable/IV were AU$187,720. Nationally, the annual estimated cost for treatment of all new cases of in situ and invasive melanomas was AU$201 million (95% CI: AU$187 to AU$216 million). When we included treatments for presumptive melanoma later found to be benign lesions, the estimated annual cost burden reached AU$272 million. Conclusion: With rapidly rising treatment costs, there is a need to consider a comprehensive melanoma control strategy that includes primary prevention of skin cancers and cost-effective sun protection initiatives.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAdis International
dc.relation.ispartofpagefrom805
dc.relation.ispartofpageto816
dc.relation.ispartofissue6
dc.relation.ispartofjournalApplied Health Economics and Health Policy
dc.relation.ispartofvolume15
dc.subject.fieldofresearchPublic Health and Health Services not elsewhere classified
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchApplied Economics
dc.subject.fieldofresearchMarketing
dc.subject.fieldofresearchcode111799
dc.subject.fieldofresearchcode1117
dc.subject.fieldofresearchcode1402
dc.subject.fieldofresearchcode1505
dc.titleEstimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorElliott, Tom MW.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record